Humanized Recombinant Anti-Human VEGF Fab fragment Antibody - 400-001-MT4-Humanized Recombinant Anti-Human VEGF Fab fragment Antibody

PRODUCT CENTER

一抗

產品中心

當前位置：首頁 > 產品中心 > 免疫學產品 > 一抗

中文名稱: Humanized Recombinant Anti-Human VEGF Fab fragment Antibody - 400-001-MT4

英文名字: Humanized Recombinant Anti-Human VEGF Fab fragment Antibody - 400-001-MT4

供應商: Rockland

產品貨號: 400-001-MT4

產品報價: ￥詢價/50ug

產品說明書: 點擊查看

購買方式: 90%產品中國有現貨庫存。銀行轉賬、電匯、支票、現金，在線支付寶及網銀支付，或直接與我們電話聯系400-6800-868

產品新聞

背景資料: VEGF is a potent mitogen in embryonic and somatic angiogenesis with specificity for vascular endothelial cells. VEGF forms homodimers and exists in four different isoforms. Overall, the VEGF monomer resembles that of PDGF, but its N-terminal segment is helical rather than extended. VEGF shares homologies of about 21% and 24% respectively with the A and B chains of human platelet-derived growth factor (PDGF), and has complete conservation of the eight cysteine residues found in both mature PDGF chains. The cysteine knot motif is a common feature of this domain. The homology is not reflected in function, however, since the cell types responsive to VEGF are distinct from those responsive to homo- and heterodimers of the PDGF chains. This protein is a glycosylated mitogen that acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. VEGF-A also has been shown to have effects on a number of other cell types (e.g. stimulation of monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells ). VEGF-A is also a vasodilator; it increases microvascular permeability, and was originally referred to as vascular permeability factor. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. Antibody against VEGF-A (Bevacizumab or brand name Avastin) is approved for treatment of cancer by inhibiting angiogenesis. Ranibizumab, a Fab fragment of Avastin or so-called Lucentis is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. This antibody is made from a humanized Fab fragment making it specific, efficient, and effective. Humanized Recombinant Anti-VEGF-A Fab fragment Antibody is useful for researchers interested in angiogenesis associated diseases such as cancer or wet AMD.

應用類型: ELISA,Flow Cytometry,Western Blot,

免疫原: 該Humanized Recombinant Anti-Human VEGF Fab fragment Antibody - 400-001-MT4的詳細信息查看Rockland提供的產品說明書。

來源宿主: 該Humanized Recombinant Anti-Human VEGF Fab fragment Antibody - 400-001-MT4的詳細信息查看Rockland提供的產品說明書。

反應性: H. sapiens (Human)

保存建議: Store vial at 2-8° C. Dilute only prior to immediate use.

其他: Rockland成立于1962年，是一家老牌抗體原產企業，其位于美國費城郊區的農場保有近20種實驗動物。Rockland公司為生命科學領域提供豐富的、高質量的抗體，包括載脂蛋白、細胞周期/凋亡、細胞因子、細胞信號蛋白、酶類、細胞外基質、轉錄因子(NFkB)和泛素（Ubiquitin）等識別抗體，應用范圍包括Western blot、免疫組化、免疫熒光和ELISA等。另外，Rockland也生產特別齊全的二抗，包括純化、生物素、HRP/ALP、熒光標記二抗，應用十分廣泛。